His scientific interests lie mostly in Internal medicine, Surgery, Cancer, Oncology and Gastroenterology. His research related to Transplantation, Leukemia, Fludarabine, Chemotherapy and Survival rate might be considered part of Internal medicine. His Surgery study combines topics from a wide range of disciplines, such as Neoadjuvant therapy, Carcinoma, Renal cell carcinoma and Odds ratio.
His work deals with themes such as Proportional hazards model, Nomogram, Soft tissue sarcoma and Pathology, which intersect with Cancer. Many of his research projects under Oncology are closely connected to Retroperitoneal liposarcoma and Atypical Lipomatous Tumor with Retroperitoneal liposarcoma and Atypical Lipomatous Tumor, tying the diverse disciplines of science together. His research in Gastroenterology tackles topics such as Immunology which are related to areas like Disease.
His primary areas of investigation include Internal medicine, Oncology, Surgery, Cancer and Gastroenterology. His research in Prostate cancer, Chronic lymphocytic leukemia, Chemotherapy, Fludarabine and Leukemia are components of Internal medicine. His research integrates issues of Disease, Pathology and Immunology in his study of Oncology.
Many of his studies on Surgery involve topics that are commonly interrelated, such as Neoadjuvant therapy. His Cancer research incorporates themes from Stage, Proportional hazards model, Retrospective cohort study and Hazard ratio. His Gastroenterology research is multidisciplinary, incorporating perspectives in Hematopoietic stem cell transplantation, Neutropenia, Toxicity, Phases of clinical research and Regimen.
His primary scientific interests are in Internal medicine, Oncology, Cancer, Gastroenterology and Cancer research. All of his Internal medicine and Chemotherapy, Neutropenia, Prostate cancer, Disease and Retrospective cohort study investigations are sub-components of the entire Internal medicine study. He focuses mostly in the field of Prostate cancer, narrowing it down to matters related to Urology and, in some cases, Statistics.
His Oncology research integrates issues from Venetoclax, Chronic lymphocytic leukemia, IGHV@, Myeloid leukemia and Hazard ratio. His Cancer study also includes fields such as
Internal medicine, Oncology, Cancer, Cancer research and Pancreatic cancer are his primary areas of study. His research links Gastroenterology with Internal medicine. His Oncology research focuses on Germline mutation and how it relates to Trisomy.
His Cancer research is multidisciplinary, incorporating elements of Standardized uptake value, Quartile and Diarrhea. His research on Cancer research also deals with topics like
Genetic heterogeneity, Gene, Mutation, Pathogenesis and Missense mutation most often made with reference to IGHV@,
Ibrutinib which connect with Neutropenia, Fludarabine, Rituximab, Cyclophosphamide and Obinutuzumab. His Pancreatic cancer research also works with subjects such as
Aerobic exercise and related Cancer treatment, Exercise program, Exercise prescription and Mean age,
Home based exercise, Quality of life, Preoperative treatment, Physical function and Adenocarcinoma most often made with reference to Prehabilitation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang.
Body surface area and body weight predict total liver volume in Western adults
Jean Nicolas Vauthey;Eddie K. Abdalla;Dorota A. Doherty;Philippe Gertsch.
Liver Transplantation (2002)
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
Marcos de Lima;Daniel Couriel;Peter F. Thall;Xuemei Wang.
Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer
Christos N. Papandreou;Danai D. Daliani;Darrell Nix;Hong Yang.
Journal of Clinical Oncology (2004)
Fingerprinting the circulating repertoire of antibodies from cancer patients
Paul J. Mintz;Jeri Kim;Kim Anh Do;Xuemei Wang.
Nature Biotechnology (2003)
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
William G. Wierda;Susan O'Brien;Xuemei Wang;Stefan Faderl.
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
Melanie B. Thomas;Romil Chadha;Katrina Glover;Xuemei Wang.
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility.
Milena S. Nicoloso;Hao Sun;Hao Sun;Riccardo Spizzo;Hyunsoo Kim.
Cancer Research (2010)
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Filip Janku;Apostolia Maria Tsimberidou;Ignacio Garrido-Laguna;Xuemei Wang.
Molecular Cancer Therapeutics (2011)
The Crosstalk of mTOR/S6K1 and Hedgehog Pathways
Yan Wang;Qingqing Ding;Chia Jui Yen;Weiya Xia.
Cancer Cell (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: